Inhibitors of the enzyme purine nucleoside phosphorylase
- 1 March 1998
- journal article
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 8 (3) , 283-299
- https://doi.org/10.1517/13543776.8.3.283
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Short-contact anthralin treatment augments therapeutic efficacy of cyclosporine in psoriasis: A clinical and pathologic studyJournal of the American Academy of Dermatology, 1995
- Enzymes of the Purine Metabolism: Inhibition and Therapeutic PotentialAnnals of the New York Academy of Sciences, 1993
- Purine nucleoside phosphorylase: A target for drug designMedicinal Research Reviews, 1993
- Phosphonate derivatives of N9-benzylguanine: a new class of potent purine nucleoside phosphorylase inhibitorsBioorganic & Medicinal Chemistry Letters, 1992
- Selective in vitro inhibition of human molt-4 T lymphoblasts by the novel purine nucleoside phosphorylase inhibitor, CI-972Biochemical and Biophysical Research Communications, 1991
- 9-(Difluorophosphonoalkyl)guanines as a new class of multisubstrate analog inhibitors of purine nucleoside phosphorylaseJournal of the American Chemical Society, 1991
- Inhibition of the enzyme purine nucleoside phosphorylase (PNP) reduces refractoriness to transfused platelets in a dog modelBritish Journal of Haematology, 1990
- Aspects of the purine nucleoside phosphorylase (PNP) deficient state produced in normal rats following oral administration of 8-amino-9-(2-thienylmethyl)guanine (PD 119,229), a novel inhibitor of PNPInflammation Research, 1987
- Preliminary report on 8-amino-9-(2-thienylmethyl)guanine (PD 119,229), a novel and potent purine nucleoside phosphorylase inhibitorInflammation Research, 1987
- 8-amino-9-substituted guanines: Potent purine nucleoside phosphorylase (PNP) inhibitorsInflammation Research, 1987